Catalog No.
Product Name
Application
Product Information
Citations
-
PPAR agonist
Rosiglitazone maleate, an antidiabetic drug, works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin.- Camilla Bean, .et al. , Nat Metab, 2021, Dec;3(12):1633-1647 PMID: 34873337
-
PPARγ agonist
Troglitazone is a selective PPARγ receptor agonist (EC50 values are 780 and 555 nM at murine and human PPARγ receptors respectively).- Gede Ngurah Rsi Suwardana, .et al. , Antiviral Res, 2025, Aug 30:243:106267 PMID: 40889532
- Julien Allard, .et al. , Cell Biol Toxicol, 2020, Jun 14 PMID: 32535746
- Gemfibrozil (Lopid) is a compound used to lower lipid levels.
- Jingyeong Shin, .et al. , Chemical Engineering Journal, 2023, December
-
PPAR agonist
Elafibranor is an agonist of the peroxisome proliferator-activated Receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.- Joost Boeckmans, .et al. , Cells, 2022, 11(5), 893 PMID: 35269515
- Tomasz Kostrzewski, .et al. , Commun Biol, 2021, 4: 1080 PMID: 34526653
- Joost Boeckmans, .et al. , MethodsX, 2020, 7: 101068 PMID: 33024711
- Joost Boeckmans, .et al. , Cell Biol Toxicol, 2020, Jul 1 PMID: 32613381
- Joost Boeckmans, .et al. , Data in Brief, 2019, June 3 PMID: 31294056
- Boeckmans J, .et al. , Pharmacol Res, 2019, Apr 24. pii: S1043-6618(18)31850-4 PMID: 31028903
-
PPAR agonist
Rosiglitazone works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin.- Sungwoo Choi, .et al. , Nat Metab, 2024, May;6(5):847-860 PMID: 38811804
-
PPAR-α/γ agonist
Aleglitazar is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM. -
PPARα/γ dual agonist
Chiglitazar is a PPARα/γ dual agonist, with EC50s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively. -
PPARδ agonist
Pparδ agonist 2 is a PPARδ agonist extracted from patent WO 2016057656 A1. -
PPAR-γ antagonist
T0070907 was identified as a potent and selective PPARgamma antagonist. With an apparent binding affinity (concentration at 50% inhibition of [(3)H]rosiglitazone binding or IC(50)) of 1 nm, T0070907 covalently modifies PPARgamma on cysteine 313 in helix 3 of human PPARgamma2. -
PPARγ agonist
Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. -
PPAR agonist
BMS-687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) alpha agonist, with an EC(50) of 10 nM for human PPARalpha and approximately 410-fold selectivity vs human PPARgamma in PPAR-GAL4 transactivation assays. - Fenofibric acid is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides.
-
PPAR agonist
Bezafibrate is the first clinically tested dual and pan-PPAR co-agonist. -
PPARβ/δ inverse agonist
DG-172 is an orally active potent PPARβ/δ inverse agonist (IC50 = 26.9 nM). DG-172 inhibits Angptl4 gene expression in mouse myoblasts (IC50 = 9.5 nM) in vitro. -
PPARγ agonist
Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. -
PPAR agonist
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively. -
PPAR-δ agonist
Seladelpar (MBX-8025) is an orally active, potent (50% effect concentration EC50 2 nM), and specific PPAR-δ agonist. -
PTP1B/IKK-βinhibitor and dual PPARα and PPARβ agonist
Ertiprotafib is an inhibitor of PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist, with an IC50 of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC50 of ~1 μM for PPARα/PPARβ. -
PPARδ agonist
Fonadelpar is a PPARδ agonist, used in the research of neuroparalytic keratopathy. -
PPAR alpha/gamma agonist
Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist that is more potent on PPARγ than on PPARα, with EC50s of 13.4 μM and 3.6 μM for rat PPARα and human PPARα, respectively. -
PPARγ agonist
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes. -
PPAR agonist
Indeglitazar is an orally available peroxisome proliferator-activated receptor (PPAR) pan-agonist for all three PPAR subtypes alpha (α), delta (δ) and gamma (γ). -
PPARγ agonist
Inolitazone a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition. -
dual α/γ PPAR activator
Peliglitazar racemate is the racemate of Peliglitazar. Peliglitazar is a novel dual α/γ PPAR activator. -
PPAR-δ agonist
Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases. -
peptidoleukotrienes antagonist
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 ?M. -
PPAR-α agonist
Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis. -
PPARα/ PPARγ1 agonist
Imiglitazar (TAK559) is a potent and dual human PPARα and PPARγ1 agonist with EC50 values of 67 and 31 nM. -
PPARδ agonist
PPARδ agonist is a PPARδ agonist extracted from patent US20180071304, compound example 10. - 4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity.
-
PPAR gamma agonist
Leriglitazone is a peroxisome proliferator activated receptor (PPAR) gamma agonist.
